These are the stocks posting the largest moves before the bell.Market Insiderread more
Target beats second-quarter earnings expectations thanks to an increase in traffic and sales. The retailer also boosts its full-year estimates.Retailread more
Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
Trump said he has "been thinking about payroll taxes for a long time" — and he cautioned that "whether or not we do something now, it's not being done because of recession."Politicsread more
Fitbit is hoping to shift its business model from relying on hardware sales to selling health plans and governments on software and services.Technologyread more
Lowe's also tops rival Home Depot on same-store sales growth in the U.S.Retailread more
"As long as the trade situation remains fluid, it will present an additional layer of uncertainty and complexity as we plan our business," Target CEO Brian Cornell said.Retailread more
Hedge funds are steering away from battered tech and semiconductor stocks, while bottom-fishing in health care names, according to Goldman Sachs.Marketsread more
President Donald Trump said on Twitter he was postponing a scheduled meeting with Denmark's prime minister because of her lack of interest in discussing a possible sale of...World Politicsread more
Dow to open higher; strong retail earnings; Gundlach says Fed lost control; negative-yielding corporate debt soars; and Trump on payroll tax cutMarketsread more
After a rush on refinances, homeowners took a breather last week, despite still seeing the lowest interest rates in about three years.Real Estateread more
Infections resistant to medicines will kill more people per year than cancer by 2050, and cost the world $100 trillion annually, according to a U.K. government-backed report led by Jim O'Neill, the well-known former Goldman Sachs economist.
The wide-ranging study, called the Review on Antimicrobial Resistance, was commissioned by the U.K. government earlier this year amid growing concerns about drug-resistant "superbugs", including new strains of E. coli, malaria and tuberculosis.
Its forecasts, based on research by RAND Europe and KPMG, suggest that drug resistance, which is estimated to have caused around 700,000 deaths globally this year, will cause 10 million by 2050 if further action is not taken.
Antibiotic use is rising around the world, while at the same time the number of new antibiotics is falling. If these medicines become ineffectual, there could be a huge economic ramifications, as people of working age are affected, and once treatable diseases become incurable again.
New antibiotics take time and money to develop, and by their nature are less effective the more they are used. As such, many pharmaceutical companies have slowed development of these kinds of drugs.
"There can be no doubt now that antimicrobial resistance is one of the biggest (risks) that we, all of us, face," Nick Stern, president of the British Academy, professor of economics and government at the London School of Economics, and former chief economist of the World Bank, said in a statement.
"The work of the group led by Jim O'Neill is of profound importance and this paper shows very convincingly the great scale of the risks, in terms of human lives and the economy, that are posed by this deeply worrying phenomenon."
Antibiotics are routinely used as part of many medical treatments, like hip replacements, Caesarean sections and chemotherapy – and these could become more dangerous if antibiotics lose their effectiveness.
O'Neill, who is best known for coming up with the acronym BRIC (Brazil, Russia, India and China) to describe the rapidly emerging economies, warned that the developing world would be hardest hit by growth in drug resistance. Countries in particular danger are likely to include India, Nigeria and Indonesia (from malaria), and Russia (from tuberculosis).
David Cameron, the U.K.'s Prime Minister, has warned of a new "dark ages of medicine" if the problem is not tackled.
- By CNBC's Catherine Boyle